Suppr超能文献

利用携带肿瘤抑制性微小RNA的胰蛋白酶处理的细胞外囊泡同时靶向肿瘤细胞和肿瘤相关巨噬细胞以重编程胶质母细胞瘤

Simultaneous Targeting of Tumor Cells and Tumor-Associated Macrophages To Reprogram Glioblastoma Using Trypsinized Extracellular Vesicles Carrying Tumor Suppressive MicroRNA.

作者信息

Nguyen Grace H, Noh MinHye, Kang Jin Muk, Miller Alexandra A, Huang Minxin, Kim Jiyeon, Lee Jeong-Yeon, Chung Sangwoon, Wang Hongyu, Calin George A, Ju Cynthia, Eltzschig Holger K, Banasavadi-Siddegowda Yeshavanth, Zhao Zhongming, Yoo Ji Young, Lee Tae Jin

机构信息

Department of Neurosurgery, McGovern Medical School, University of Texas Health Science Center at Houston, 6431 Fannin Street, Houston, Texas 77030, United States.

Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center-UT Health at Houston, 6767 Bertner Avenue, Houston, Texas 77030, United States.

出版信息

Nano Lett. 2025 May 21;25(20):8414-8422. doi: 10.1021/acs.nanolett.5c01897. Epub 2025 May 13.

Abstract

Glioblastoma (GBM) remains difficult to treat due to poor drug delivery across the blood-brain barrier and an immunosuppressive tumor microenvironment (TME). Tumor-suppressive microRNAs (miRNAs) offer a promising strategy to reprogram both tumor cells and the TME, but inefficient delivery systems limit their clinical application. We previously reported that tumor-suppressive miR-138 regresses tumor growth in preclinical GBM models. Here, we demonstrate that trypsin digestion of extracellular vesicles (EVs) enhances labeling efficiency with folate (FA), enhancing selective targeting of folate receptor (FR)-positive GBM cells and enabling simultaneous targeting of tumor-associated macrophages (TAMs). FA-labeled trypsinized EVs (tEVs) loaded with miR-138 inhibit tumor growth, depolarize TAMs, and enhance antitumor immunity. This study represents the first preclinical attempt to modulate tumor cells and innate immunity via miRNA-loaded tEVs, offering a novel and more effective therapeutic approach to GBM treatment.

摘要

由于药物难以穿过血脑屏障以及免疫抑制性肿瘤微环境(TME),胶质母细胞瘤(GBM)仍然难以治疗。肿瘤抑制性微小RNA(miRNA)为重新编程肿瘤细胞和TME提供了一种有前景的策略,但低效的递送系统限制了它们的临床应用。我们之前报道过,肿瘤抑制性miR-138在临床前GBM模型中可使肿瘤生长消退。在此,我们证明对细胞外囊泡(EV)进行胰蛋白酶消化可提高叶酸(FA)标记效率,增强对叶酸受体(FR)阳性GBM细胞的选择性靶向,并能够同时靶向肿瘤相关巨噬细胞(TAM)。装载有miR-138的FA标记胰蛋白酶处理的EV(tEV)可抑制肿瘤生长,使TAM去极化,并增强抗肿瘤免疫力。本研究是首次通过装载miRNA的tEV调节肿瘤细胞和先天免疫的临床前尝试,为GBM治疗提供了一种新颖且更有效的治疗方法。

相似文献

本文引用的文献

4
Therapeutically harnessing extracellular vesicles.治疗性利用细胞外囊泡。
Nat Rev Drug Discov. 2022 May;21(5):379-399. doi: 10.1038/s41573-022-00410-w. Epub 2022 Mar 2.
6
Extracellular vesicles as a next-generation drug delivery platform.细胞外囊泡作为下一代药物递送平台。
Nat Nanotechnol. 2021 Jul;16(7):748-759. doi: 10.1038/s41565-021-00931-2. Epub 2021 Jul 1.
9
The Risks of miRNA Therapeutics: In a Drug Target Perspective.miRNA 治疗的风险:从药物靶点角度看。
Drug Des Devel Ther. 2021 Feb 22;15:721-733. doi: 10.2147/DDDT.S288859. eCollection 2021.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验